MetrioPharm AG
MetrioPharm AG initiates development program for emergency medication against epidemic infections
MetrioPharm AG / Miscellaneous Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- MetrioPharm AG initiates development program for emergency medication against epidemic infections Zurich, May 8. 2009: Swiss MetrioPharm AG (WKN: AOMLMB; ISIN; CH0029188817) is currently giving a series of company presentations in Germany, Switzerland and the UK. Within this context the company introduces its new development program for an emergency drug against acute epidemic infectious diseases. Against the background of swine-flu, recent evidence pointing to the high effectiveness of one of MetrioPharm's pipeline drug compounds in acute and potentially lethal infections are gaining importance. A series of experiments over the past 12 months documented the efficacy and safety of the compound. It could be shown, that the examined compound was able to prevent the lethal outcome that viral infections can take if left untreated or if anti-viral treatment is not effective. 'These results show that we have pinpointed a new treatment approach which may prove to be an effective weapon against aggressive and highly infectious agents. Especially with the risk of a global epidemic in mind, these results are of high significance to us', said Dr. Wolfgang Brysch, president of the Managing Board of MetrioPharm AG. Experts of the World Health Organization (WHO) keep warning against the threat of a global epidemic caused by infectious agents which may cause deadly infections when transmitted from animals to humans. In past years, the risk of such a rapidly spreading global epidemic has risen significantly. Reasons are, among others, the rise of intensive mass-production of animals in developing countries coupled with increased rate of global travel, which aids the spread of new infections across continents. The potentially high spreading speed of such an epidemic poses almost insurmountable challenges to governments and local health authorities. In case of a new viral infection, for example, there is not enough time to develop a vaccine. Next to anti-viral drugs like Tamiflu, new therapeutics are needed, which prove to act quickly and effectively against yet unknown infective agents. 'The compound currently under investigation at MetrioPharm meets exactly these requirements: Efficacy against a potentially wide spectrum of infections, simplicity of use as well as suitability for long-term storage and immediate availability in case of emergency.' describes Dr. Brysch the key features of the new therapeutic approach. About MetrioPharm AG: MetrioPharm AG is a biotechnology company which focuses on the development and registration of small-molecular drugs in advanced developmental stages, for which there is already clinical evidence for efficacy in humans. Company Contact: MetrioPharm AG Neuendorfstrasse 20B 16761 Hennigsdorf www.metriopharm.com T. +49 (0) 3302 20 234 02 F. +49 (0) 3302 20 234 99 info@metriopharm.com Investor Relations Contact: GFEI Gesellschaft für Effekteninformation mbH Hamburger Allee 26-28 60486 Frankfurt am Main www.gfei.de T. +49 (0) 69 743 037 00 F. +49 (0) 69 743 037 22 metriopharm@gfei.de 08.05.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found